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Abstract
Background: Copy number gains and amplifications are characteristic feature of cervical cancer (CC) genomes for
which the underlying mechanisms are unclear. These changes may possess oncogenic properties by deregulating tumor-
related genes. Gain of short arm of chromosome 5 (5p) is the most frequent karyotypic change in CC.
Methods: To examine the role of 5p gain, we performed a combination of single nucleotide polymorphism (SNP) array,
fluorescence in situ hybridization (FISH), and gene expression analyses on invasive cancer and in various stages of CC
progression.
Results: The SNP and FISH analyses revealed copy number increase (CNI) of 5p in 63% of invasive CC, which arises at
later stages of precancerous lesions in CC development. We integrated chromosome 5 genomic copy number and gene
expression data to identify key target over expressed genes as a consequence of 5p gain. One of the candidates identified
was Drosha (RNASEN), a gene that is required in the first step of microRNA (miRNA) processing in the nucleus. Other
5p genes identified as targets of CNI play a role in DNA repair and cell cycle regulation (BASP1, TARS, PAIP1, BRD9, RAD1,
SKP2, and POLS), signal transduction (OSMR), and mitochondrial oxidative phosphorylation (NNT, SDHA, and NDUFS6),
suggesting that disruption of pathways involving these genes may contribute to CC progression.
Conclusion:  Taken together, we demonstrate the power of integrating genomics data with expression data in
deciphering tumor-related targets of CNI. Identification of 5p gene targets in CC denotes an important step towards
biomarker development and forms a framework for testing as molecular therapeutic targets.
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Background
The short arm of chromosome 5 (5p) frequently under-
goes nonrandom changes in cervical cancer (CC) by
exhibiting both copy number increase and deletions. Gain
of 5p due to frequent appearance of isochromosome 5p in
squamous cell carcinoma has been documented by karyo-
typic and chromosomal comparative genomic hybridiza-
tion analyses [1-4]. Paradoxically, 5p also exhibits
frequent loss of heterozygosity, which occurs early in the
development of CC [5,6]. These findings suggest the pres-
ence of important proliferation-regulating genes on chro-
mosome 5p involved in malignant progression of cervical
epithelium.
Despite the successful use of pap-smear screening pro-
grams in early detection and treatment of CC, this tumor
remains a major cause of cancer deaths in women world-
wide [7]. CC progresses by distinct morphological
changes from normal epithelium to carcinoma through
low-grade squamous intraepithelial lesions (LSIL) and
high-grade SILs (HSIL). Currently, no biological or genetic
markers are available to predict which precancerous
lesions progress to invasive CC. Although infection of
high-risk human papillomavirus (HPV) is recognized as
an essential initiating event in cervical tumorigenesis, this
alone is not sufficient for the progression to invasive can-
cer [8]. In spite of the recent progress in molecular aspects
of CC, the genetic basis of progression of precursor SILs to
invasive cancer in the multi-step progression of CC
remains poorly understood [9]. Therefore identification
of other "genetic hits" in CC is important in understand-
ing its biology.
Chromosomal gain and amplification is a common cellu-
lar mechanism of gene activation in tumorigenesis [10].
The aim of the present study was to examine the contribu-
tion of chromosome 5 copy number alterations (CNA) in
CC tumorigenesis and identify copy number driven gene
expression changes. We performed single nucleotide pol-
ymorphism (SNP) array and fluorescence in situ hybridi-
zation (FISH) analysis on invasive cancer and identified
5p CNI in a high frequency of primary tumors and cell
lines. To unravel the consequence of 5p CNI on transcrip-
tion, we utilized Affymetrix U133A gene expression array
and identified a number of over expressed genes on 5p,
which include RNASEN, POLS, OSMR, and RAD1 genes.
These data, thus, suggest that transcriptional activation of
multiple genes on 5p plays a role as driver genes in the
progression of CC.
Methods
Tumor specimens and cervical cancer cell lines
A total of 219 specimens were utilized in the present study
in various investigations. These include 9 cell lines, 148
primary tumors, 42 pap smears, and 20 normal cervical
tissues. The cell lines (HT-3, ME-180, CaSki, MS751, C-4I,
C-33A, SW756, HeLa, and SiHa) were obtained from
American Type Culture Collection (ATCC, Manassas, VA)
and grown in tissue culture as per the supplier's specifica-
tions. Twenty age-matched normal cervical tissues from
hysterectomy specimens obtained from Columbia Uni-
versity Medical Center (CUMC), New York, were used as
controls after enrichment for epithelial cells by microdis-
section. Cytologic specimens were collected using the
ThinPrep Test Kit (Cytc Corporation, Marlborough, MA).
After visualization of the cervical os the ectocervix was
sampled with a spatula and endocervical cells obtained
with a brush rotated three hundred sixty degrees. Exfoli-
ated cells were immediately placed in PreservCyt Solution
(Cytc Corporation, Marlborough, MA) for routine
processing by a cytopathologist. Pap smears were col-
lected from normal and precancerous lesions by simulta-
neous preparation of slides from the same spatula for
both cytology and FISH. FISH slides were immediately
fixed in 3:1 methanol and acetic acid, and stored at 4°C
until hybridization. A total of 42 pap smears with the
diagnosis rendered by a cytopathologist as normal/squa-
mous metaplasia/ASCUS (N = 10), LSIL (N = 13) or HSIL
(N = 19) obtained from CUMC were used for FISH analy-
sis. The diagnosis of all HSILs was also confirmed by a
biopsy. Of the 148 primary tumors, 93 were obtained as
frozen tissues and 55 specimens as formalin-fixed paraf-
fin-embedded tissues. All primary invasive cancer speci-
mens were obtained from patients evaluated at CUMC,
Instituto Nacional de Cancerologia (Bogota, Colombia)
[11], and the Department of Gynecology of Campus Ben-
jamin Franklin, Charité-Universitätsmedizin Berlin (Ger-
many) with appropriate informed consent and approval
of protocols by institutional review boards. All primary
tumors were diagnosed as squamous cell carcinoma
(SCC) except five that were diagnosed as adenocarcinoma
(AC). Clinical information such as age, stage and size of
the tumor, follow-up data after initial diagnosis and treat-
ment was collected from the review of institutional medi-
cal records. Tissues were frozen at -80°C immediately
after resection and were embedded with tissue freeze
medium (OTC) before microdissection. All primary
tumor specimens were determined to contain at least 60%
tumor by examination of hematoxylin and eosin (H&E)
staining of adjacent sections. High molecular weight DNA
and total RNA from tumor, normal tissues, and cell lines
was isolated by standard methods. The integrity of all
RNA preparations was tested by running formaldehyde
gels and samples that showed evidence of degradation
were excluded from the study.
Microarray analysis
The Affymetrix 250 K NspI SNP chip was utilized for copy
number analysis as per the manufacturer's protocol.
Briefly, 250 ng of genomic DNA was digested with NspI,Molecular Cancer 2008, 7:58 http://www.molecular-cancer.com/content/7/1/58
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generic linkers were added followed by PCR amplifica-
tion, end-labeling, and fragmentation following standard
protocols. Hybridization, washing, acquisition of raw
data using GeneChip Operating Software (GCOS), and
generation of .CEL files was performed by the Affymetrix
Core facility at our institute. We utilized 79 CC cases (9
cell lines and 70 primary tumors enriched for tumor cells
by microdissection) and 7 microdissected normal cervical
squamous epithelial samples as controls to serve as refer-
ence for copy number analysis. SNP data of test samples
and normal cervical epithelial specimens were loaded to
dChip to calculate signal intensity values using the perfect
match/mismatch (PM/MM) difference model followed by
normalization of signals within chip and between chips
using model-based expression [12,13]. DNA copy
number gains were obtained as determined by dChip
using analysis of signal intensity values based on the Hid-
den Markov Model. Arrays with > 93% call rates were
included in the analysis as per Affymetrix manual. Copy
number data was obtained for chromosome 5 using Cyto-
Band information files from the dChip website [14]. Both
the raw copy number and log2 ratio (Signal/mean signal
of normal samples at each SNP) were computed to esti-
mate copy number changes in chromosome view. Copy
numbers < 1.5 were considered as deletion, 2.5 or more as
gain in the raw copy number view. All the original data
files were submitted to Gene Expression Omnibus (GEO
Accession number: GSE10092).
We utilized Affymetrix U133A oligonucleotide microarray
(Santa Clara, CA) containing 14,500 probe sets for gene
expression analysis. RNA isolated from 30 CC cases (21
primary tumors enriched for tumor cells by microdissec-
tion and 9 cell lines) and 20 microdisssected normal cer-
vical squamous epithelial cells were utilized for
expression studies. Biotinylated cRNA preparation and
hybridization of arrays was performed by the standard
protocols supplied by the manufacturer. Arrays were sub-
sequently developed and scanned to obtain quantitative
gene expression levels. Expression values for the genes
were determined using the Affymetrix GeneChip Operat-
ing Software (GCOS) and the Global Scaling option,
which allows a number of experiments to be normalized
to one target intensity to account for the differences in glo-
bal chip intensity. The .CEL files obtained from the GCOS
software were processed and normalized by dChip algo-
rithm as described above. An average percent present call
of 54% was obtained among all samples, which is
expected for high quality RNA as per the manufacturer.
Arrays were normalized at PM/MM probe level and a
median intensity array from normal as the baseline array
using invariant set normalization [12,13]. Followed by
normalization, model based expression values were calcu-
lated using PM/MM data view to fit the model for all
probe sets. All original data files were deposited to GEO
(Accession number: GSE9750). To obtain a list of differ-
entially expressed gene signatures, we compared all nor-
mal with all tumor samples using the criteria of 1.75-fold
change between the group means at 90% confidence
interval and a significance level of P < 0.05. All negative
expression values for each probe set were truncated to 1
before calculating fold changes and < 10% of samples
with present call in each group were excluded. A list of dif-
ferentially expressed genes identified on chromosome 5
was used in all subsequent supervised analyses using the
same criteria between various groups to obtain relevant
gene signatures.
Fluorescence in situ hybridization (FISH) and HPV typing
FISH was performed by standard methods on frozen tis-
sue sections fixed in 3:1 methanol: acetic acid, tissue
microarrays prepared from paraffin embedded tissues,
and on pap smears fixed in 3:1 methanol: acetic acid. A
dual color locus specific probe set containing spectrum
orange labeled EGR1 (map to 5q31) and spectrum green
labeled D5S23/D5S721 (map to 5p15.2) was obtained
from Vysis (Downers Grove, IL). Hybridization signals on
100–500 interphase cells on DAPI counterstained slides
were scored on Nikon Eclipse epi-fluorescence micro-
scope equipped with Applied Imaging CytoVision soft-
ware (San Jose, CA). Scoring of FISH signals on frozen and
paraffin-embedded tissue sections was restricted to tumor
cells based on the identification of areas of tumor on adja-
cent H&E sections by the pathologist (MM). FISH signal
scoring on Pap smear slides was restricted to large and
atypical epithelial cells. Presence of signals suggestive of
gain in at least 3% cells was considered positive and the
results correlated with parallel cytomorphologic findings.
Human papillomavirus types were identified as described
earlier [15].
Results
Identification of 5p gain as the most frequent genomic 
alteration in invasive CC
Affymetrix 250 K NspI SNP array analysis was performed
on a panel of 79 CC cases (70 primary tumors and 9 cell
lines) to identify genome-wide copy number alterations
(CNA) (unpublished data). The dataset of chromosome 5
CNA from this analysis was utilized in the present study.
CNA of chromosome 5 was found in 42 (53.2%) CC
cases. Of these, 5p exhibited copy number gains in 34
(43%) cases while no detectable copy number losses were
found on this chromosomal arm (Figure 1A). Gain of 5p
was the most commonly affected regions in the CC
genome (see Additional file 1). On the other hand, gain of
long arm of chromosome 5 (5q) was rare with only 3
(3.8%) tumors showing CNI. However, copy number
losses on 5q were found in 25 (31.6%) tumors. Of these,
17 had concurrent 5p gains and 5q losses, while the
remaining 8 only showed 5q deletion (Figure 1B). AmongMolecular Cancer 2008, 7:58 http://www.molecular-cancer.com/content/7/1/58
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the tumors that exhibited 5p CNI the entire 5p was gained
and no minimal region of duplication or amplification
could be delineated. Similarly, deletions on 5q span large
regions often spanning the entire chromosomal arm and
no consensus minimal deletion could be identified (Fig-
ure 1B). This data demonstrate that the chromosome 5p is
a frequent target of CNI in CC, while accompanying dele-
tions on 5q were found less frequently. To identify the
clinical significance, we evaluated the association of chro-
mosome 5 CNA with pathologic features such as histol-
ogy, age, stage and size of the tumor, treatment outcome,
and HPV type by univariate analyses and found no signif-
Identification of chromosome 5p genomic alterations in cervical cancer Figure 1
Identification of chromosome 5p genomic alterations in cervical cancer.A-B. Copy number alterations in log2 ratio 
of chromosome 5 identified by 250 K NspI SNP array. Each vertical column represents a sample with genomic regions repre-
senting from pter (top) to qter (bottom). Prefix "T" indicates primary tumor; "CL" indicates cell line. The blue-red scale bar (-
1 to +1) at the bottom represents the copy number changes relative to mean across the samples. The intensities of blue and 
red indicate relative decrease and increase in copy numbers, respectively. G-banded ideogram of chromosome 5 is shown on 
the extreme right in each panel. A. Identification of 5p gain as the most frequent genomic alteration in CC. All tumors that 
exhibited 5p gain are shown. Inferred copy number view of HeLa cell line showing 5p gain from normal (2N) (red line) is shown 
on right. B. 5q deletions in CC. All tumors that exhibited 5q deletions arranged from largest to smallest deletion are shown. 
Inferred copy number view of T-1875 showing 5q deletion from normal (2N) (red line) is shown on right. C-F. Fluorescence in 
situ hybridization (FISH) identification of 5p gains in invasive cancer (C-E) and high-grade cervical intra-epithelial lesion (HSIL) 
(F). Green signals represent 5p15.2 probe and Red signals represent probe mapping to 5q31 region used as control. Panels C-
D represent invasive CC cases with increased copies of 5p (green) compared to 5q (red). Note the concordance of SNP copy 
number changes (panel A) and increased copies of 5p by FISH (panels C-E) for tumors T-207, T-218, and T-1981, respectively. 
Panel F showing 4 copies of chromosome 5p and 5q (tetrasomy 5) on a pap smear from HSIL.Molecular Cancer 2008, 7:58 http://www.molecular-cancer.com/content/7/1/58
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icant associations. These data thus suggest that chromo-
some 5 CNA is a critical genetic alteration that may occur
early in the development of CC.
FISH validation of 5p gain in CC
To validate the 5p gain identified by SNP array, we per-
formed FISH analysis using a cocktail of two probes con-
taining spectrum green-labeled 5p15.2 locus and
spectrum orange-labeled 5q31 region on 101 CC cases.
These include an independent panel of 55 tumors on a
paraffin-embedded tissue microarray and an additional
46 tumors as frozen sections or pap smears. The latter
include 23 tumors studied by SNP array (see Additional
file 2). A total of 64 (63%) tumors showed an evidence for
increased copies (3 or more) of 5p (Figure 1C–E). An aver-
age of 4.4 copies (range 3–11) of 5p15 signals were found
among the 64 cases that exhibited gain, while only 2.6
copies (range: 1–8) of the 5q31 region were present (Fig-
ure 1C–E). These data, thus, suggest that the 5p CNI is
independent of ploidy of the tumor and support the SNP
data showing the gain of 5p and associated loss of 5q.
All the tumors that exhibited 5p gain by SNP array also
showed gain by FISH. For example, the tumors T-207, T-
218, and T-1981 showed simultaneous high copy num-
bers of 5p and loss of 5q by SNP array analysis. The FISH
results on the same tumors are in complete agreement
with the SNP data (Figure 1). These results, thus, validate
the SNP data and establish that 5p CNI as the most fre-
quent genetic alteration in CC.
Chromosome 5p gain is a late genetic event in CC 
progression
CC progresses through distinct morphological changes
during the transition from normal epithelium to carci-
noma through low- and high-grade SILs. To identify the
earliest stage in CC development in which the 5p CNI
occur, we used a FISH assay on 42 consecutively ascer-
tained pap smears simultaneously diagnosed by cytology
as normal, squamous metaplasia or with atypical cells of
undetermined significance (ASCUS) (N = 10), LSIL (N =
14) and HSIL (N = 19). Five of 19 (26.3%) HSILs showed
four or more copies (range 4–7) of 5p (Figure 1F). Of
these, three HSILs exhibited tetrasomy 5 while 2 others
showed evidence of 5p gain (5–7 copies vs. 3–4 copies of
5q) (Figure 1F). No evidence of gain of 5p was found in
any specimens diagnosed as LSIL, normal, squamous
metaplasia or ASCUS. Thus, these data suggest that 5p
gain is a relatively late event in the progression of CC.
The biological behavior of HSILs varies where only a small
proportion progresses to invasive cancer if left untreated
[16-18]. Cytologic characterization alone doesn't permit
the identification of HSILs at risk for progression from
those that regress or persist. Because of this, all HSILs are
currently treated by surgical excision or with an ablative
therapy. Identification of genetic signatures defining the
subset of high-risk HSILs could alter the treatment strate-
gies. Chromosome 5p gain may serve as such a genetic
marker in predicting the progression of HSILs.
Identification of transcriptional targets of 5p gain, 
including Drosha, in CC
We have shown 5p CNI as the most frequent genomic
alteration in CC by combined SNP (see Additional file 1)
and FISH analyses. We hypothesize that the increased 5p
dosage may result in deregulation of genes that may con-
fer oncogenic properties to its host cell. To identify such
transcriptional targets on 5p, we utilized gene expression
profiling data on Affymetrix U133A array analysis of 20
normal squamous epithelial samples (age range, 27–64
yr; Mean ± SD, 46.9 ± 7.6) and 30 CC cases (21 primary
tumors; age range 28–70 yr; Mean ± SD, 48.3 ± 11.3; and
9 cell lines). Initial identification of differentially
expressed gene signatures on chromosome 5 in CC was
obtained by comparison of all probe sets on chromosome
5 present in U133A array between tumors and normal
that exhibit significant (P < 0.05) differences using the cri-
teria described in materials and methods. This algorithm
identified 122 non-redundant probe sets with significant
differences in expression levels in tumors compared to
normal. This unique CC chromosome 5 gene signature,
which distinguishes normal from tumor, includes 26
probe sets with down-regulated expression and 96 probe
sets with increased expression (see Additional file 3). We
anticipate that this differentially expressed gene data set
will be useful in identifying target genes of CNI of 5p and
loss of 5q in CC. Therefore, we focused our attention on
this gene dataset in all subsequent supervised analyses of
gene expression.
To further identify over expressed genes on 5p, we then fil-
tered all over expressed probe sets on chromosome 5
against all 5p probes on U133A array and this analysis
showed enrichment for over expressed genes by identify-
ing 26 genes (LOC728411,  PDCD6,  RAI14,  SLC12A7,
DAP,  Hs.561432,  MYO10,  OSMR,  BASP1,  C5orf28,
TRIP13,  NNT,  TARS,  PAIP1,  CCT5,  SDHA,  NDUFS6,
BRD9,  KIAA0947,  FASTKD3,  RAD1,  BXDC2,  SKP2,
C5orf22, POLS, and RNASEN) (see Additional file 4). We
then asked whether the over expression of these 26 genes
in CC compared to normal squamous epithelia is due to
a generalized tumor-related transcriptional deregulation
or is a consequence of 5p CNI. To examine this, we filtered
the 26 over expressed gene data set by comparison
between tumors exhibited 5p gain (N = 17) and tumors
with disomy 5p (N = 13) by SNP analysis. This supervised
analysis identified 17 differentially over expressed genes
(OSMR,  BASP1,  C5orf28,  TRIP13,  NNT,  TARS,  PAIP1,
SDHA, NDUFS6, BRD9, FASTKD3, RAD1, BXDC2, SKP2,Molecular Cancer 2008, 7:58 http://www.molecular-cancer.com/content/7/1/58
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C5orf22, POLS, and RNASEN) only in tumors exhibiting
5p CNI (Figure 2). Therefore, these 17 genes represent
copy number driven target over expressed genes that likely
provide growth advantage and invasion conferred by
chromosome 5p gain.
Although a similar type of analysis identified down-regu-
lated gene signature on 5q in invasive CC, no specific sig-
nature associated with 5q deletion could be identified
(see Additional file 5). Analysis performed to identify the
down regulated genes on 5q using all probes on chromo-
some 5q on U133A array showed a total of 17 down reg-
ulated genes (EGR1, PITX1, MAST4, GALNT2, ATP10B,
DUSP1, HBEGF, RMND5B, HMGCR, CAST, CLTB, GX3,
SPINK5, LOC653314, CXCL14, ISL1, and PIK3R1) in CC
compared to normal cervical epithelium. Thus, these data
suggest that the 5p gain is a critical genetic change in CC
and the genes identified as a consequence of 5p gain may
be important in its tumorigenesis. These data further sug-
gest that the 5q loss may have little consequence to CC
biology and may represent a by-stander genetic alteration
associated with 5p gain.
Discussion
We provide multiple levels of evidence to support that
genomic gain of chromosome 5p is an important genetic
target in CC development. First, our SNP analysis identi-
fied 5p gain as the most frequent genetic alteration in
invasive CC (see Additional file 1). By FISH we confirmed
this finding using an independent cohort of CC speci-
mens and seen only in high-grade SILs. Several previous
studies have identified recurrent gain of 5p in many types
of human cancers [19], including CC [1-4,20-22]. Gain of
5p also appears to arise at latter passages in HPV-immor-
Supervised analysis of over expressed genes identified as a consequence of gain of chromosome 5q in cervical cancer Figure 2
Supervised analysis of over expressed genes identified as a consequence of gain of chromosome 5q in cervical 
cancer. Significantly differentially expressed genes were identified by filtering all the over expressed genes on chromosome 5p 
between tumor that showed gain of 5p and tumors with out 5p gain. In the matrix, each row represents the gene expression 
relative to group mean and each column represents a sample (shown on Top). T, represents primary tumor; CL, represents 
cell line. The dendrogram on left shows unsupervised clustering of genes differentially expressed between tumors with and 
without gain. The names of genes are shown on right. The scale bar (-2 to +2) on the bottom represents the level of expres-
sion with intensities of blue represents decrease and red for increase in expression. The groups within tumors shown at top 
represent no gain of chromosome 5p (I) and 5p gain (II).Molecular Cancer 2008, 7:58 http://www.molecular-cancer.com/content/7/1/58
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talized cervical keratinocytes and its acquisition confers
the ability to invade collagen in tissue culture [23]. This
close recapitulation of 5p gain in latter stages of an in vitro
model and in the clinical specimens from CC patients
provide a strong evidence that this change occurs late in
the development and may play role in invasion.
Second, we have identified concurrent over-expression
(2.2 to 6.0-fold) of genes with 5p gain relative to GAPDH
expression (Table 1, Figure 3). Several genes that we found
up-regulated in this study as a consequence of 5p gain are
potentially relevant to cellular processes associated with
tumorigenesis such as signal transduction (OSMR),
nucleic acid binding, DNA repair, mitotic cycle (BASP1,
TARS, PAIP1, BRD9, RAD1, SKP2, and POLS), oxidative
phosphorylation (NNT, SDHA, and NDUFS6), HPV 16 E1
binding protein (TRIP13) [24], ribosomal synthesis
(BXDC2), micro RNA processing (RNASEN).
Of these genes, RNASEN (Drosha) over expression was
identified in all tumors with 5p gain ascertained by SNP
analysis (Figure 2). This finding suggests that RNASEN is
one of the critical targets conferred by 5p CNI that may
play a major role in tumor progression. Drosha executes
the initial step in microRNA (miRNA) processing by
cleaving pri-miRNA to release pre-miRNA. Drosha is also
involved in pre-rRNA processing with specificity to dou-
ble-strand RNA [25]. Drosha over expression was shown
to regulate proliferation and predicts poor prognosis in
esophageal cancer [26]. Drosha copy number gain and
over expression was shown to influence global miRNA
profiles in CC [27]. miRNAs play critical roles in various
biological processes including cancer where miRNA fin-
gerprinting can distinguish different lineage tumors [28].
Although the role of Drosha over expression in cancer is
not well studied, a number of possibilities exist. Overex-
pressed Drosha may more efficiently process pri-miRNAs
resulting in increased levels of mature miRNAs and the
resulting miRNAs may effect transcription of several
mRNAs that in turn affect the production of other pri-
miRNAs [29]. In the context of its role in miRNA process-
ing, our data suggest that Drosha over expression due to
5p gain is likely an important mechanism in later stages of
CC progression.
Previous studies have shown that oncostatin M receptor
(OSMR) gene is gained and over expressed in CC, which
is associated with adverse clinical outcome [30,31].
Oncostatin M (OSM) is a cytokine related to the IL-6 fam-
ily of cytokines and its biological activity is mediated
through the receptor complex. Upon ligand binding,
OSMR can activate signaling pathways implicated in can-
cer such as STAT, PI3/AKT, and mediates inhibition of
tumor growth [32]. Angiogenic factor VEGF is induced
upon OSM stimulation in cervical cancer cell lines sug-
gesting OSMR over expression contributes in CC tumori-
genesis [31].
Our expression analysis also showed a number of genes
that possess functions related to nucleic acid binding,
DNA repair, and mitotic cell cycle (BASP1, TARS, PAIP1,
BRD9,  RAD1,  SKP2, and POLS). Of these, the S-phase
kinase-associated protein 2 (SKP2) plays a critical role in
coordinating the G1/S transition, cell cycle progression,
forms a substrate recognition subunit of SCF ubiquitin-
protein ligase complex, and inhibits the tumor suppressor
Table 1: Over expressed genes as a consequence of chromosome 5p gain in cervical cancer
Gene Description Function Role in cancer Average fold change#
OSMR Oncostatin M receptor Signal transduction [31] 3.1
BASP1 Brain abundant, membrane attached signal protein 1 DNA binding - 6.0
C5orf28 Chromosome 5 open reading frame 28 Not known - 2.9
TRIP13 Thyroid hormone receptor interactor 13 HPV16 E1 protein binding protein [24] 5.0
NNT Nicotinamide nucleotide transhydrogenase Detoxification of ROS - 3.7
TARS Threonyl-tRNA synthetase Aminoacylation of tRNA - 3.2
PAIP1 Polyadenylate-binding protein-interacting protein 1 Translation activator activity - 2.3
SDHA Succinate dehydrogenase complex, subunit A, 
flavoprotein
Oxidative phosphorylation - 3.4
NDUFS6 NADH dehydrogenase (ubiquinone) Fe-S protein 6 Oxidative phosphorylation - 2.3
BRD9 Bromodomain containing 9 Nucleic acid binding - 2.2
FASTKD3 FAST kinase domains 3 Unknown - 2.4
RAD1 RAD1 homolog DNA repair, cell cycle check point - 3.2
BXDC2 Brix domain containing 2 Ribosomal biosynthesis - 2.6
SKP2 S-phase kinase-associated protein 2 Mitotic check point [33] 3.6
C5orf22 Chromosome 5 open reading frame 22 Unknown - 3.0
POLS Polymerase (DNA directed) sigma DNA repair - 2.8
RNASEN Ribonuclease III, nuclear miRNA processing [27] 2.8
# Fold-change is calculated based on comparison between normal cervical squamous epithelium and tumors with Chr5p gainMolecular Cancer 2008, 7:58 http://www.molecular-cancer.com/content/7/1/58
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function of FOXO1. Over expression of SKP2 was found in
many tumor types, consistent with a role of an oncogene,
and is associated with poor clinical outcome [33]. RAD1
is a component of the 9-1-1 cell-cycle checkpoint response
complex that plays a major role in DNA repair [34]. How-
ever, its role in cancer is not well understood. Three
nuclear genes (NNT,  SDHA, and NDUFS6) encoding
mitochondrial proteins that play a role in oxidative phos-
phorylation (OxPhos) were also over expressed as a con-
sequence of 5p gain. The mitochondrial OxPhos system
plays a key role in energy production, the generation of
free radicals, and apoptosis, the hallmark features of can-
cer cells [35]. Since tumor cells display enhanced biosyn-
thesis capacity, a key feature of the metabolic
transformation of tumor cells that support growth and
proliferation, the mitochondrial OxPhos system may
stimulate signaling pathways critical in tumor progres-
sion. Although nothing is known about these genes in
cancer, it remains to be determined whether one or more
of these genes act individually or synergistically as onco-
genes in regulating the metabolic transformation in CC.
Since genetic activation of therapy targets such as ABL, C-
KIT, Her2/neu, and EGFR has been successfully demon-
strated to be essential for treatment response [36], our
finding of 5p gene targets such as RNASEN, SKP2, and
OSMR emphasize the need for functional analysis and
dissecting signaling cascades involving these genes in ulti-
mately obtaining therapeutic targets needed for cure and
prevention of this devastating cancer.
Conclusion
In summary, we integrated multiple genomic data to iden-
tify 5p gain as the most recurrent chromosomal alteration
Relative expression of differentially expressed genes as a consequence of 5p gain in relation to GAPDH in normal and tumors  with and without gain of 5p gain Figure 3
Relative expression of differentially expressed genes as a consequence of 5p gain in relation to GAPDH in nor-
mal and tumors with and without gain of 5p gain. Genes are shown on top left-side corner of each panel.Molecular Cancer 2008, 7:58 http://www.molecular-cancer.com/content/7/1/58
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that occur at high-grade precancerous lesions in the devel-
opment of CC. We identified the target 5p gain associated
over expressed genes that play a role in miRNA processing,
signal transduction, DNA repair and mitotic cycle, and
oxidative phosphorylation, suggesting a functional role
for this chromosomal region in progression of CC. Thus,
the genes identified here will form a basis for functional
testing of 5p gain and the gene expression levels can be
used as a biomarker to identify patients with aggressive
disease. Further studies in the context of 5p gain will allow
deciphering critical gene targets to develop molecular
based therapies for CC.
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